Home / Transcripts / Aarti Drugs Limited (524348) · May 18, 2026

Aarti Drugs Limited (524348) Earnings Call Transcript & Summary

May 18, 2026

BSE Limited IN Health Care Pharmaceuticals earnings 52 min

What were the key takeaways from Aarti Drugs Limited's May 18, 2026 earnings call?

In Q4 FY '26, Aarti Drugs Limited reported a revenue of INR 721.1 crores, marking a 6% year-on-year increase and a significant 20% quarter-on-quarter growth. However, net profit (PAT) decreased by 12% year-on-year to INR 55.3 crores, despite a 36% increase from the previous quarter. Management indicated that FY '27 EBITDA margins are expected to range between 13.5% to 14%, slightly lower than previous targets due to ongoing geopolitical challenges affecting input costs.

What topics did Aarti Drugs Limited cover?

What were Aarti Drugs Limited's May 18, 2026 results?

Aarti Drugs Limited's Q4 FY '26 results reflect a mixed performance with revenue growth overshadowed by declining profitability. The company's strategic focus on regulated markets and formulation growth is promising, but ongoing geopolitical challenges and input cost pressures pose risks. Investors should monitor the ramp-up of new facilities and the antibiotic segment's performance as key indicators for future growth.

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone, and welcome to the Q4 FY 2026 earnings conference call for Aarti Drugs Limited. During this call, we may make forward-looking statements regarding the company, and those are based on what the company believes, its opinions, and its expectations as of today, the date of this call. Such statements do not constitute guarantees of future results and carry risks and uncertainties that are hard to foresee. Just a reminder that every participant line will be in listen-only mode, and after the presentation ends there will be a chance for you to ask questions. If you require help at any point during the call, please signal an operator by pressing star then zero on your touchtone phone. Kindly note that this conference is being recorded. I now hand the conference over to Mr. Adhish Patil, COO and CFO from Aarti Drugs Limited. Thank you, and over to you, Mr. Patil.

Adhish Patil executive
#2

Thank you. Good morning, everyone, and welcome to Aarti Drugs Limited's Q4 and FY 2026 earnings conference call. With me today are Mr. Harshit Savla, Joint Managing Director; Mr. Harit Shah, Whole-time Director; Mr. Vishwa Savla, Managing Director of Pinnacle Life Science Private Limited; and our investor relations advisors, SGA. We hope you've had a chance to go through our financial results and investor presentation for the quarter and full year ended 31st March 2026, both of which have been filed with the stock exchanges and are also available on our website. I'll begin by walking you through the key business and financial highlights for the period. FY 2026 was a significant execution year for Aarti Drugs, as we transitioned out of the investment phase and into the operational scale-up phase. Looking at the industry more broadly, FY 2026 stayed difficult owing to a range of macroeconomic and geopolitical uncertainties, among them global trade disruptions, trade tariffs and GST changes, and pricing volatility. As FY 2026 drew to a close, we faced elevated input costs and constraints in the supply chain for crude and gas-based raw materials stemming from the West Asia War. Freight, packaging, utility, and energy-related costs also stayed high during the quarter. Meanwhile, the availability of certain key raw materials was inconsistent at various points.

Adhish Patil executive
#3

Even though the industry faced a tough operating climate, the business closed out the year on far firmer ground, with a sharp sequential rebound in Q4 FY 2026. Operational efforts — process optimization, alternate sourcing strategies, energy efficiency measures, and tighter planning — allowed us to offset a portion of those pressures and keep operations running without interruption. Next, we'll cover the consolidated financial highlights. Q4 FY 2026 revenue came in at INR 721.1 crores, against INR 678.6 crores in Q4 FY 2025 and INR 602.9 crores in Q3 FY 2026, which works out to 6% growth year-on-year and 20% quarter-on-quarter, respectively. EBITDA was INR 96.6 crores, versus INR 95.2 crores in Q4 FY 2025 and INR 56.3 crores in Q3 FY 2025, pointing to flattish year-on-year growth and roughly 72% growth on a quarter-on-quarter basis. EBITDA margin came in at 13.4%. Tax was INR 55.3 crores, compared with INR 62.8 crores in Q4 FY 2025 and INR 40.5 crores in Q3 FY 2026 — a de-growth of 12% year-on-year and up to 36% Q on Q increase. Tax margin worked out to 7.7% for Q4 FY 2026. Turning to the standalone business highlights for Q4 FY 2026, revenue was INR 631.7 crores, versus INR 623 crores in Q4 FY 2025.

Adhish Patil executive
#4

On a standalone basis, our business accounted for roughly 88% of consolidated revenue. Of that standalone top line, 63% was generated domestically and 37% came from exports. Domestic revenue was up 7% year-on-year, while export revenue fell 7% year-on-year. Inside the API business, the antibiotic therapeutic category made up about 37.8%, anti-protozoal about 19.6%, anti-inflammatory about 11.9%, anti-diabetic 15%, antifungal around 10%, and the remaining roughly 5.7% of total API sales came from the rest. Now let me turn to the formulation segment highlights. Formulation revenue came in at INR 91.3 crores, versus INR 64.8 crores in Q4 FY 2025, which is a 41% increase year-on-year. Exports made up 69% of that revenue. For FY 2026, formulation revenue reached INR 330.5 crores against INR 284.9 crores in FY 2025, a rise of 16%, with exports representing 65% of total formulation sales. Volume growth in the domestic market stayed healthy, and we saw momentum in select non-antibiotic and export-led products. Export markets, particularly formulations, proved to be a key growth driver that supported overall business stability. As we highlighted on slide 10 of our investor presentation, Aarti Drugs has delivered positive volume growth consistently over the last five years, even as the industry faced sharp pricing corrections. Although this pricing pressure weighed on realizations and top line growth sector-wide, our capacity to sustain volumes and maintain customer relationships is a reflection of the trust our clients place in us.

Adhish Patil executive
#5

On a positive note, pricing patterns began to steady starting in September 2025, and that rebound gained more traction in Q4 FY 2026, helped by rising crude prices, and should lift realizations over the near term. One major driver of our results this quarter was the ongoing ramp-up of our new manufacturing site, particularly our backward integration plant for methylamines at Saykha. That facility scaled up substantially and was run at higher utilization levels, where operational performance stayed encouraging. Although the early ramp-up period brought some temporary headwinds, the plant reached a production rate of almost 1,000 tons per month in March 2026. We anticipate making additional progress on utilization ramp-up in FY 2027. In time, this project should greatly cut reliance on inputs sourced externally and boost self-sufficiency for the metformin portfolio, thus aiding margin improvement and operating leverage. A further significant structural gain in FY 2026 was the growing contribution from regulatory and export-oriented markets. Export contribution rose from 35% in FY 2025 to 38% in FY 2026, and within that, regulated market contribution also climbed to 73% from 66%. This steady move toward regulated markets and higher value products reflects the company's capacity to satisfy stringent regulatory norms and comply with international quality standards.

Adhish Patil executive
#6

All in all, FY 2026 was still a year of operational transition, yet we closed it out with notably better momentum. That was helped along by pricing trends settling down, exports coming in stronger, an improving product mix, and newly commissioned facilities ramping up gradually. So with that, I'd like to turn things over now to questions. Thank you.

Operator operator
#7

Thank you. We're moving into the Q&A portion now. To ask a question, you can dial star one on your touchtone phone. Should you want to drop out of the queue, just press star two. We ask that participants use their handsets when posing a question. Ladies and gentlemen, we'll hold for a moment while the queue is put together. Our first question is from Nilesh Ghuge of HDFC Securities. Please go ahead. Mr. Ghuge, go ahead with your question. Mr. Ghuge, please unmute and proceed with your question. As we haven't received a response from Mr. Ghuge's line, we'll go to the following participant. That is Mr. Shashank Koil from Pyumara Capital. Please go ahead.

Shashank Koil analyst
#8

Hi there. Yes, thanks a lot for kicking things off and for those really strong figures. My first question is this: how is the methylamines plant progressing in its ramp-up, and what kind of realization has it gotten to so far?

Operator operator
#9

Mr. Koil, apologies for cutting in. Mr. Koil, we can't hear you clearly. Would you mind moving closer and speaking up?

Shashank Koil analyst
#10

Yes. Hi there. Is my voice coming through okay?

Operator operator
#11

Yes, please go ahead.

Shashank Koil analyst
#12

Yeah, my question is this: how is the plant ramping up? What kind of integration has it achieved so far, and what do you expect over the next two years? Aarti's plant.

Adhish Patil executive
#13

Is it the methylamine plants in Saykha that you mean?

Shashank Koil analyst
#14

Yeah, yeah.

Adhish Patil executive
#15

Right, so that facility only came online during September. Our December quarter marked the first period in which we posted utilization at approximately 29%, more or less. When we got to the March quarter, we managed to reach 40% or a bit above 40%. We came in slightly under the 45 to 50% goal we had set, and the main reason was the ammonia-based feedstock at that facility, tied to the conflict in West Asia. Looking ahead, we expect that during the June quarter we ought to comfortably exceed roughly 55 to 60% utilization at that facility. Within 12 months, our belief is that we should be running the methylamine plants at above 70% utilization.

Shashank Koil analyst
#16

Alright, alright. Moving on to salicylic acid — could you share what profitability was at the capital level in the prior quarter, and what kind of margin and revenue profile it might achieve across the coming few quarters, assuming the duty structure stays the same?

Adhish Patil executive
#17

Right. Salicylic acid continues to be a laggard. As we discussed, last quarter one piece of equipment was slated to arrive in late April. We made a decision, since we were incurring variable losses on salicylic acid — we couldn't recover and bring down raw material cost owing to the absence of that equipment. We chose to halt net production, and once every piece of equipment is running, once testing is done, once variable costs are under control, we'll then resume manufacturing salicylic acid. That's the most recent update on salicylic acid. We do expect and hope we'll improve, and very quickly we should begin forward integration of salicylic acid too, because that plant has already been commissioned. Now we'll need to carry out piloting and scale up the derivatives plant.

Shashank Koil analyst
#18

All right, many thanks. That's everything from my side. Thanks.

Adhish Patil executive
#19

I appreciate that.

Operator operator
#20

Thanks. Just a quick reminder for everyone on the line: you can hit star and one whenever you'd like to ask something. Our next question is from Dhwanil Desai at Turtle Capital. Go ahead, please.

Dhwanil Desai analyst
#21

Hello, and good morning, Adhish. First off, I have a question. In your comments you noted that Q4 finished on a strong note and that realizations had also been stabilizing somewhat — you know, thanks to this Russia conflict, there is some improvement. With that in mind, since we already have substantial capacity in place and the negative rate variance now lies behind us, should we be looking for 10%, 12% volume growth, and perhaps 4%, 5% positive rate variance, given the regulated market's contribution is rising and, overall, the incremental pricing we're securing because of the hand?

Adhish Patil executive
#22

Right. As things stand, API prices are still high owing to the war in West Asia. Should that go on for a longer stretch, there will certainly be significantly greater favorable rate variances. Even so, we will keep aiming to hit volume growth of, you know, 8% to 10%. As you mentioned, we have also, you know, already added capacity through two greenfield expansions. Reaching that level of volume — that sort of volume growth — ought to be pretty straightforward. On realizations, they will certainly be positive. The more the war drags on, the bigger the favorable variance will be.

Dhwanil Desai analyst
#23

Understood. One more question on that, Adhish. So, we're discussing volume growth of 8%-10%. When you consider the past 2 years, we've invested heavily in CapEx, and additional capacity is now being commissioned. Given that, if we're referring to 8%-10% volume growth, does that imply that for the existing base business we aren't anticipating much volume growth? Because that seems a bit on the low side, considering the new capacity across so many new products—salicylic acid, methylamine, Specialty Chemicals. With all of that in place, why would we, at a company level, only grow volume at 8%-10%?

Adhish Patil executive
#24

Yes. The internal goal is going to stay at 10%-15% growth. At the moment, what's happening is that with pricing very high in the antibiotic segment, what we saw last time was domestic demand falling off. That's our worry. If crude prices stay very elevated, the older generation molecules — which, you know, are already being sold at a much cheaper rate in the Indian market, and there's a degree of price regulation for the formulation players — when the API becomes very expensive, typically demand for those products declines. That's what we observed during the Russia-Ukraine war as well in 2023. That's the only challenge we think we could face for the antibiotic category in the domestic market if prices are too high. If prices are moderate, then demand won't be affected. If they're too high, if crude remains too high, then probably that might be the reason.

Dhwanil Desai analyst
#25

Understood. On the second question about gross margin, I believe there is a bit of improvement on a standalone basis, you know, where gross margin is concerned. How should we view gross margin, considering that realizations have risen while input cost has also increased? At the same time, the regulated piece is scaling up somewhat. You know, the rupee has depreciated, imports, exports. Several factors are coming into play here. Given all of this, are we expecting any change in gross margin for the year ahead?

Adhish Patil executive
#26

The key point is that we don’t really anticipate much change in gross margins. In any case, we performed fairly well on gross margins in Q4. What we’d like to do is keep gross margins at this kind of level. In Q4, our manufacturing costs were a little higher, though they could come down by a percent or so, and that could lead to an improvement in EBITDA margin. That said, there are two factors: the more regulated sales that we’re targeting will help raise the gross margin. On the other side, if API prices rise too much because of raw material prices, what typically happens is that, in order to maintain a certain level of ops—absolute gross profit per kg of a product—the margin tends to fall in terms of gross margin. You see my point?

Dhwanil Desai analyst
#27

Correct.

Adhish Patil executive
#28

If we are making-

Dhwanil Desai analyst
#29

Correct.

Adhish Patil executive
#30

Yeah, 36%.

Dhwanil Desai analyst
#31

You're making an absolute point, and I hear you — the absolute figure can rise, but on a percentage basis it'll appear on the lower end since we are, you know

Adhish Patil executive
#32

In the event that pricing rises.

Dhwanil Desai analyst
#33

Okay, understood. My point is this: as a percentage, it might not rise much—perhaps it levels off or dips a little—but on an absolute basis, if the delta is larger, does that imply the flow-through into EBITDA would be considerably stronger, and therefore the EBITDA margin as well?

Adhish Patil executive
#34

Yes, it can. That’s a possibility.

Dhwanil Desai analyst
#35

Understood. Understood. The third item, and the final question, concerns the formulation side. We performed very strongly there. So, what factors are contributing? I believe our oncology piece remains — the dossiers are still going through approval, so that will require some time. What's fueling this growth? Looking ahead, a run rate like this one is, you know, something we can sustain. How ought we to view that?

Adhish Patil executive
#36

Yes. Vishwa, do you want to take that question?

Vishwa Savla executive
#37

Yeah, absolutely. As you mentioned, our oncology facility hasn’t started generating revenue yet — the growth we’re seeing right now comes from direct exports within the non-oncology portfolio. Because our roster of approved products across regulated markets keeps expanding, that’s the part of the business that’s scaling fast, and that’s why exports are climbing too, which is also driving improved margins. Looking forward, we anticipate a solid number of approvals along with market extensions, and those should let us continue growing the export business at a similar rate.

Dhwanil Desai analyst
#38

Regarding the 90 crores run rate we achieved, I think that figure is something that can be sustained in FY 2027. Is that a fair way to look at it?

Vishwa Savla executive
#39

Yes. Yes, yes, that’s a reasonable assumption. Yes.

Dhwanil Desai analyst
#40

Understood — thanks. That’s all. Best wishes.

Adhish Patil executive
#41

I appreciate that.

Operator operator
#42

Thanks. Just a quick reminder to everyone that you can hit star and one if you'd like to ask something. Our next question is from Jai Jain with <<inaudible>>. Go ahead, please.

Analyst analyst
#43

Hello, sir. Sir, I have a few questions. First, sir, as you pointed out, the regulated market contribution rose substantially in FY 2026. Which main geographies are driving that gain, and which products?

Adhish Patil executive
#44

Yes. I want to point out that these would mostly be Latin American markets. Even so, the European and U.S. markets would remain our target for more regulated sales as we move forward. We haven't seen an uptick in that yet, but it looks very promising, since a lot of business development — a lot of business development activity — is underway with these clients. A lot of approvals are also coming through for the facility and for the product. That means within a year, at least toward the end of the year, we should begin to see some flow in the regulated markets from our U.S. FDA plant that was recently reapproved, as well as from other products. In fact, at many of our other dedicated plants too, we have taken CEPs, which are the European approvals, for antifungal products. We have them for anti-inflammatory as well. Yeah. Is there anything else you're asking?

Analyst analyst
#45

Yes. Sir, second, could you give us a status update on the timeline for the key U.S. FDA approvals and the DMF filing across APIs and formulations?

Adhish Patil executive
#46

Regarding APIs?

Analyst analyst
#47

Yeah.

Adhish Patil executive
#48

Regarding API, the U.S. FDA approval came through last year — the plant approval. There are a few antibiotic, anti-inflammatory and a few other therapies that we're actively marketing in the U.S. market, and we expect the flows to begin within 12 to 18 months. We also have oncology for the U.S. markets, where we're filing dossiers in the formulation business.

Analyst analyst
#49

And finally, could you also give us an update on where things stand with the anti-dumping duty on the acyclovir products?

Adhish Patil executive
#50

Could you say that again? I couldn’t hear you.

Analyst analyst
#51

Could you give us an update on where things stand with the anti-dumping duty on the acolyte products? Sorry.

Adhish Patil executive
#52

All right. If I understood your question correctly, what you're getting at is anti-dumping.

Analyst analyst
#53

On the anti-dumping duty question — yes.

Adhish Patil executive
#54

Yeah, yeah.

Analyst analyst
#55

Regarding the acolyte products.

Adhish Patil executive
#56

Yeah. What I mean is, right now we’re going through the application process for our

Analyst analyst
#57

Salicylic acid.

Adhish Patil executive
#58

That's salicylic acid, and it's still in progress. Right now, as we speak, the application has been filed, and we're moving forward through the different stages of that anti-dumping duty application.

Analyst analyst
#59

All right, all right. Appreciate it. Thanks.

Adhish Patil executive
#60

Thanks.

Operator operator
#61

Thanks. Just a quick reminder for everyone on the line: you can hit star and one whenever you'd like to ask a question. Our next question is from Sajal Kapoor at Antifragile Thinking. Go right ahead.

Sajal Kapoor analyst
#62

Yeah, thanks for the chance to ask. Adhish, I came onto the call a bit late, so I didn't catch your opening remarks. Sorry about that. My questions might be somewhat different. First, I mean, when it came to the methylamines ramp up, which challenges were kind of external and beyond management's control, like the ammonia shortage and volatility in raw materials.

Adhish Patil executive
#63

My apologies for cutting in.

Sajal Kapoor analyst
#64

Apologies — something’s interfering with the connection.

Adhish Patil executive
#65

One of the lines is picking up some interference.

Operator operator
#66

Just a moment, please, while I check. Speaker, the disruption is originating from Mr. Harshit Savla's line. You have the floor.

Sajal Kapoor analyst
#67

Alright. Alright, thanks. Hello, Adhish. Which difficulties during the Saykha ramp-up fell kind of, you know, beyond what you could control or came from outside — I mean, could it be an ammonia shortfall, volatility in raw materials, or some other elements? And which challenges were kind of internal execution matters where, you know, we or the company misjudged schedules, utilization curves, or the complexity of operations? Since greenfield plants are always tough when it comes to scaling up, right? What frequently works at the design stage doesn't actually materialize in the—

Adhish Patil executive
#68

Correct.

Sajal Kapoor analyst
#69

So what I mean is, if you could break down your answer into the part that was internal and might have been handled better, versus the factors beyond your control, and then how we ought to view that within this specific amines, Greenfield, as we move into FY 2027, this fiscal year. Thank you.

Adhish Patil executive
#70

We mentioned the Saykha plant a bit earlier. We stated that we began this plant—the first quarter being the December quarter, when the plant operated at full scale. Just give me a minute. Previously we could only reach a run rate of roughly slightly under 30% utilization during the month—in the December quarter. In the March quarter, despite the fact that there were minor raw material shortages, we managed to achieve utilization above 40%, a little over 40%. As for what we are observing in the first half of Q1, we have already used the plant at about 60%, the Saykha plant. The methylamines ramp-up is going quite well. We did not encounter many problems at this plant, unlike the Tarapur facility for salicylic acid. However, better utilization of this plant will depend somewhat on our expansion plans for metformin itself, which are also underway as we speak right now. We are expanding metformin production as well. The more metformin production, the more utilization of the Saykha plant. As for internal problems, there are very minor issues with the drying of one of the methylamines derivatives.

Adhish Patil executive
#71

Right now that doesn’t concern us, since we can still raise utilization, and in maybe 3 or 4 months the Saykha plant’s true profitability should begin delivering results.

Sajal Kapoor analyst
#72

Sure. No, that helps. Adhish Patil, on the metformin side, how much of the value chain do we actually control at this point? You see, the situation across India overall with metformin in particular was that nobody — truly nobody — had any backward integration, correct?

Adhish Patil executive
#73

Understood.

Sajal Kapoor analyst
#74

Everybody relied on China. How—

Adhish Patil executive
#75

Precisely.

Sajal Kapoor analyst
#76

What's the current state of things on the ground now when it comes to metformin, as far as Aarti Drugs is concerned?

Adhish Patil executive
#77

When it comes to metformin, there are two key intermediates. One comes from China and Europe, while the other is made locally — meaning it's sourced domestically. As for DCDA, which is imported, plenty of companies are involved in it, and there isn't much margin to be had in that product right now. On top of that, it involves an exclusive chemistry and hazardous chemistry when it comes to manufacturing. As for the locally sourced intermediate for metformin, my belief is that as of today we're the only company with a backward integration facility. That places us in a really strong position. We were already highly cost competitive in metformin, since we were clearly the leader — with a handsome majority — when it comes to selling metformin in semi-regulated markets, or I won't call them unregulated, because no API market is unregulated as of today. I'd say that apart from the highly regulated markets, in the ROW market we were the absolute leader in metformin, where production cost matters a great deal. With this backward integration coming in, our cost will drop even further. Another significant update on metformin: we have already filed a DMF with the U.S. for metformin. Now, gradually, once we ramp up capacity, we'd like to invite the FDA to inspect our dedicated metformin facility.

Adhish Patil executive
#78

So that would be the next step for metformin. We've already got the European approval, but our view is that U.S. approval is the key — even for selling metformin into European markets.

Sajal Kapoor analyst
#79

All right, that helps. Since our backward integration projects are ramping up now, would it be reasonable to expect year-over-year improvement in margins each year, even if not quarter-over-quarter? The business economics are straightforward. Fixed costs stay fixed, correct? That holds as utilization rises, provided realizations aren't taking a big hit, right? There's also anti-dumping discussion going on, coming out of China. With all of that in mind, is it fair to expect at least 100 to 200 basis points of EBITDA margin improvement in FY 2027?

Adhish Patil executive
#80

Yeah, that should — in terms of cost contribution, we can expect that. We can definitely target at least 100 basis points.

Sajal Kapoor analyst
#81

When do we think we'll return to that sunny-days situation, or where do we see that happening? Back in the 2015, 2016, 2017 period, we were posting 16% operating margins fairly consistently.

Adhish Patil executive
#82

Okay.

Sajal Kapoor analyst
#83

We're nowhere near that figure. I realize 2021, the COVID year, stood out as an exception when we reached 20%, a level that was never sustainable.

Adhish Patil executive
#84

Okay.

Sajal Kapoor analyst
#85

With the kind of business we run, having backward integration and with this formulation now also ramping up — you know, at some point the onco facility will come into play as well. I mean, do you really believe that a 16% margin at the EBITDA level is still a challenge even now?

Adhish Patil executive
#86

So taking all of that into account — with more regulated sales coming from our USFDA plant, and with metformin securing USFDA approval, which we're hopeful about — plus with the arrival of formulation, formulation exports have already gone up, and EBITDA margins in the formulation business now sit upwards of 16%-17%, which is very good for us, and that held steady across the last two quarters. With the oncology business coming in, as utilization rises, we will certainly begin adding margin at the EBITDA level. Because even right now we are expensing a portion of oncology cost — developmental cost — partly within the P&L. As oncology sales get better, EBITDA margins should definitely get better as well.

Sajal Kapoor analyst
#87

Could you remind me once more what the CapEx plan looks like for this fiscal year and the one after, since I may have missed it?

Adhish Patil executive
#88

Okay. At this point, we aren't pursuing what you'd call a Greenfield project — though you could describe it as quasi Greenfield, meaning it sits somewhere between Brownfield and Greenfield. The reason is that the expansion — the new product, the production lines, the new production plants being set up — is mainly coming up in blocks adjoining the existing facilities. On the whole, the capital requirement would be a bit lower than for Greenfield projects, since with Greenfield projects, plot development, your compound wall, your utility setups, your other admin setup, QC block setup — those absorb a lot of funds. In this type of expansion, what we're doing and planning right now — and overall plans exist in about three to four locations — it will need somewhat less CapEx, but the asset turn on that CapEx should be a little higher, because it's quasi Greenfield, or Brownfield as you might say. The overall project — what this is, I was referring to the standalone. Plus, in formulations we're also coming up with an additional block, because we already have an EDQM block in formulation for OSD. I'm talking about other than non-onco. We want to double that capacity, and we want to make that block EDQM as well.

Adhish Patil executive
#89

Taking everything into account, our sense is that over the coming two to three years — at minimum two to three years — roughly INR 300 to 400 crores of CapEx could well be deployed. Once again, that CapEx would be a prudent one, aimed more at boosting the capability we already have rather than moving into entirely new products. In formulation, though, a portion of this CapEx will also be directed toward formulation for building out our oncology product basket, since that calls for heavy CapEx. Some of the CapEx will go into the formulation business. We expect our formulation business to grow, you know, at least up to INR 1,000 within the next three to five years.

Sajal Kapoor analyst
#90

Okay. So, how much of this expansion is supported by actual customer discussions and visibility into demand or orders, as opposed to, you know, wanting to have the capacity ready in hopes that demand will show up—

Adhish Patil executive
#91

Under-

Sajal Kapoor analyst
#92

Regarding capital expenditures?

Adhish Patil executive
#93

Got it. Got it. When it comes to the standalone business, since these are Brownfield or quasi-Greenfield types of projects, every one of these products is something we already work in. We have fairly solid visibility into what demand for that product will be. It's supported by conversations and discussions with customers. On the formulation side, I would — Vishwa, could you just walk through how we're approaching formulation demand going forward? Hello? Vishwa, are you on the line?

Operator operator
#94

Mr. Savla, the floor is yours.

Vishwa Savla executive
#95

My apologies — the audio is cutting out on my end a little. Would you mind going over that final section once more? It didn't come through clearly for me.

Adhish Patil executive
#96

Yes, let me explain that, Vishwa—

Vishwa Savla executive
#97

Yeah.

Adhish Patil executive
#98

That's the question, um—

Vishwa Savla executive
#99

Yeah.

Adhish Patil executive
#100

The CapEx we're undertaking over the coming 2 years—

Vishwa Savla executive
#101

Correct.

Adhish Patil executive
#102

Or perhaps a span of three years.

Vishwa Savla executive
#103

Right, right.

Adhish Patil executive
#104

When it comes to that CapEx figure, I’d like to know what portion is supported by visible demand or actual customer conversations, and what portion is more speculative — like, you know, we’ll have this ready and then presumably demand will show up? That’s my question.

Vishwa Savla executive
#105

Okay, let me break this down for you. CapEx really falls into two categories. The first is our capacity enhancement program, which is largely driven by what we forecast for signed products — or where we have clear visibility that once our products launch, we'll require those volumes. This is a brownfield expansion meant to support the growth we're projecting from both existing products and new ones. Now, regarding CapEx for R&D development, that typically works like this: we focus on developing products first, and then, once those products reach late-stage development — whether the dossiers are ready or close to approval — that's the point where we begin signing contracts. Aside from a handful of contracts signed very early on, the majority get signed when products are nearly ready for the market.

Sajal Kapoor analyst
#106

All right. All right. No, that helps. Thanks. I appreciate you taking all my questions, team, and best of luck. Thanks.

Vishwa Savla executive
#107

Thanks.

Adhish Patil executive
#108

All right, thank you.

Operator operator
#109

Thanks. Our following question is from Meghna Agarwal at Mount Intra. The floor is yours.

Meghna Agarwal analyst
#110

Hi there. Thanks for having me. Can you hear me okay?

Operator operator
#111

Ms. Agarwal, could you speak up just a bit more?

Meghna Agarwal analyst
#112

Yeah. Yeah, hello there. Hi — can you hear me okay?

Operator operator
#113

Yes, go right ahead.

Meghna Agarwal analyst
#114

Yeah. Thanks for giving me the chance. Actually, could you just walk me through, you know, that thing about the salicylic acid? I didn't quite catch it properly. Like, we're restarting production, so what actually happened? Could you please explain it to me?

Adhish Patil executive
#115

Right. So with salicylic acid, there's a lot that needs improving at the process level. One issue involved phenol recovery — it was being lost as waste on the mother liquor side. We actually ran trials a few months ago. We'd already placed the order for the equipment too. It should be installed at any moment now. Until that equipment goes in, and we run it and confirm it's working the way it should — although we've done pilot batches, so ideally it ought to perform correctly — only after that do we see room for us to move into variable profit on salicylic acid. Without that equipment in place, there's no reason to push ahead with producing more salicylic acid, since doing so would just create bigger losses for us. At the same time, on salicylic acid, here's what we've done: we've already commissioned — it's essentially at a late stage — we're moving into salicylic acid derivatives. The reason is that derivative selling prices are significantly higher, so the potential for margin expansion is greater if you go ahead and sell derivatives directly.

Adhish Patil executive
#116

Second, we're also pursuing anti-dumping measures on salicylic acid. Third, there's another area for improvement with salicylic acid, and that's on the effluent side. What happens in China is that the effluent stream is simply saline water — highly saline water — and they're permitted to discharge it into the sea, since no other impurities are present in it. We're exploring the possibility with the government, because if we had to evaporate all of that, you know, that leaves us somewhat behind when competing with China. That's that. There are two or three challenges. We're addressing all of them at once. One is the liquid-liquid extractor I mentioned for enhancing phenol recovery. The second was cutting costs on the effluent side. Third is anti-dumping duty. Fourth is the derivatives plant, which will be up by the end of May or at the latest by mid-June. There's a serious shortage of fabrication labor, which we saw during the summer season, partly also due to a lack of cooking gas and all. The labor isn't available in the area. That's why the plant was delayed a little. In any case, it will be finished soon.

Adhish Patil executive
#117

It's a multi-pronged approach, you know, that we're pursuing in order to improve the salicylic acid, and after that we'll restart the facility.

Meghna Agarwal analyst
#118

All right. And I also wanted to ask whether there's any revenue guidance or EBITDA guidance for FY 2027 — what are we expecting there?

Adhish Patil executive
#119

So look, we've already come in at over 13% on EBITDA margin. Obviously, the war is a major challenge — how things will develop, how high crude prices might climb, whether they'll remain elevated for a really extended stretch, or whether they'll hover around, say, 90 or 100, which is fine, which is pretty reasonable. There's a bit of uncertainty, but hoping for the best, we'd still like to aim for EBITDA margins somewhere in the 13.5%–14% range for this FY 2027. If that war weren't happening, our prior targets were certainly 14%–14.5% EBITDA margin for FY 2027.

Meghna Agarwal analyst
#120

Okay, and then one final question, if I may. I’d like to get a sense of what’s going on in the antibiotic segment. Are we seeing any kind of recovery there, or what exactly is happening in that antibiotic segment, please?

Adhish Patil executive
#121

We did see a bit of a rebound quarter over quarter — that is, March compared with the December quarter. One factor that could put additional pressure on antibiotic demand is the higher cost of antibiotics, meaning the raw materials and so on. If crude stays elevated — that is, above $110 or $120 — then in the near term it could weigh on domestic antibiotic demand, in all likelihood. That's our view.

Meghna Agarwal analyst
#122

Thanks. In the antibiotic sector, are we seeing any growth in volume or in price? And for our company, what are we seeing?

Adhish Patil executive
#123

Price growth is happening at the moment. Speaking on a year-on-year basis, that means in FY 2027 we expect a very large increase in prices for antibiotics. Where volumes are concerned, they may stay a bit flattish — I say flattish because, in any case, the volumes for antibiotics in FY 2026 were not that great, so in our belief they will not decline any further.

Meghna Agarwal analyst
#124

Alright, perfect. Thanks a lot, and best of luck.

Adhish Patil executive
#125

Alright, thanks.

Operator operator
#126

Thanks. The next question is from Nilesh Ghuge at HDFC Securities. Go ahead. Mr. Ghuge, please proceed with your question. Mr. Ghuge, please unmute and ask your question. As there's no response from Mr. Ghuge's line, we'll go to the next participant, Rishabh Jain with Modi Capital. Please go ahead.

Rishabh Jain analyst
#127

Hi there, can everyone hear me?

Operator operator
#128

Yes.

Rishabh Jain analyst
#129

Thanks for taking my question. Management mentioned during the quarter that API price increases were selective. Which products saw those hikes, and how sustainable are they? Should we expect more increases going forward?

Adhish Patil executive
#130

Harit, would you mind taking this question?

Harit Shah executive
#131

No, no. At this point prices have leveled off. We don't anticipate any additional price hikes. That said, it will certainly hinge on where raw materials and crude oil prices stand, basically. Right now all solvents and other chemicals sit at peak levels, and we don't see them climbing further unless crude exceeds $140 — you know, $130, $140, but.

Rishabh Jain analyst
#132

All right. Given what you said about crude, is there any shortage of key raw materials at the moment stemming from the war, and does that affect the business in any way?

Harit Shah executive
#133

No. The only problem we ran into was back in March, when we had some trouble sourcing raw materials — ammonia, mostly. Beyond that, raw material availability isn't a concern for us right now.

Rishabh Jain analyst
#134

Alright, alright, thanks. That's everything from me. Thanks.

Operator operator
#135

Thanks. Our next question is from Resham Jain at VVD Asset Managers. Go ahead, please.

Resham Jain analyst
#136

Hello, and good morning, sir. I’ve got two or three questions. The first one concerns the total CapEx you referred to — INR 300 crore to INR 400 crore across the coming three to four years. Since cash generation is fairly healthy and we always keep some amount of debt equity, are you planning any additional CapEx beyond that? It won’t line up with overall cash generation over the next three to four years.

Adhish Patil executive
#137

If we see something that looks more lucrative, there's a chance we'd replace part of the CapEx. Should the two current Greenfield projects — Saykha and the salicylic one — show a stark improvement in cash flow, then we could probably work with a bigger budget too, since cash generation would then be much higher than it is today. Based on today's financials, this much is quite easily doable. Even as of today, our consolidated long-term debt stands at around INR 328 crores, and short-term debt would be around INR 248 crores. The debt to equity ratio is also at its historically lowest as of today in this quarter.

Resham Jain analyst
#138

Yeah, exactly. That's the reason I raised the question. It's possible that by the time the year wraps up, you might do a bit more fine-tuning on the total CapEx budget.

Adhish Patil executive
#139

Right. Right. That's 100% right.

Resham Jain analyst
#140

All right, regarding the second question about the CWIP of INR 214 crores that's currently sitting there — which projects does that relate to, sir?

Adhish Patil executive
#141

What's the amount? CWIP — what figure did you mention?

Resham Jain analyst
#142

I can see INR 214 crore.

Adhish Patil executive
#143

Right, right. Part of that was tied to the cogen boiler, along with some brownfield expansions we're carrying out. And a big chunk of it also relates to formulation R&D — the dossiers, the oncology dossiers we're developing. That, you know, takes a huge amount of CapEx as well. Once we secure the approval, that's when the amortization of those CapEx will begin.

Resham Jain analyst
#144

The bulk of that should be capitalized this year, correct? FY 2027, perhaps the first half.

Adhish Patil executive
#145

Uh-

Resham Jain analyst
#146

Oncology is the exception, though.

Adhish Patil executive
#147

Vishwa, could you share your view on oncology — if those projects go live this year and next year, how much would we get, I mean, in percentage terms?

Vishwa Savla executive
#148

Yes, I believe his question leaves out oncology. Essentially, on the formulation side, project life cycles run quite long, and most of the CWIP will begin being amortized across the coming 24 months. Certain portions may be amortized during this year and the next, though the bulk of it would come after 24 months.

Resham Jain analyst
#149

Alright, got it. Got it. Sir, one final question. This year, across all the projects that have kicked off — the methylamine and the salicylic acid and the rest — what's the total EBITDA loss sitting there for this year? Because there'll be a fair amount of ramp-up-related cost.

Adhish Patil executive
#150

Mm-hmm. So you mean the full year, for FY 2026?

Resham Jain analyst
#151

Across the full year, how much EBITDA loss in total stems from the new projects?

Adhish Patil executive
#152

If you want my rough guess, the EBITDA loss alone for the whole year would land somewhere around INR 18 crore to INR 20 crore.

Resham Jain analyst
#153

Got it, sir. Thanks very much, and all the best to you.

Adhish Patil executive
#154

Thanks.

Vishwa Savla executive
#155

Thanks.

Operator operator
#156

Appreciate it.

Adhish Patil executive
#157

Thanks.

Operator operator
#158

That wraps up the questions from everyone. That was the final question we had for today. Our question and answer session has now come to a close. At this point, I'll turn the conference back over to management for their closing remarks.

Adhish Patil executive
#159

Thanks. I appreciate you raising those questions and for the interest you’ve shown in Aarti Drugs. With utilization getting better at the facilities we’ve recently commissioned, and as the payoff from our strategic investment begins to show up more substantially in operations, we anticipate profitability and return ratios improving steadily over the years ahead. We stay dedicated to disciplined execution, operational excellence, and creating sustainable long-term value for every one of our stakeholders. Thank you again for your ongoing support and for your confidence in Aarti Drugs. Should you have any additional questions, please contact SGA, our investor relations advisors. Thank you. Have a nice day.

Operator operator
#160

Thank you. That brings this conference to a close on behalf of Aarti Drugs Limited. We appreciate your participation. You can go ahead and disconnect your line now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Aarti Drugs Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Aarti Drugs Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.